{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:28:15Z","timestamp":1770748095844,"version":"3.49.0"},"reference-count":73,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,6,18]],"date-time":"2012-06-18T00:00:00Z","timestamp":1339977600000},"content-version":"vor","delay-in-days":17,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2012,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The disease activity measures in rheumatoid arthritis (<jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content>) have a lot of unmet need for current clinical demand. With available biological and aggressive disease modifying anti\u2010rheumatic drug therapy, the goal of <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> treatment has moved toward remission or at least tighter control. The current measures lose their ability to discriminate further once the patient gets into minimal disease or tight control. There are more numbers of parameters, measured to assess disease activity, like joint counts, perception scales and laboratory parameters. There are different composite scores like <jats:styled-content style=\"fixed-case\">D<\/jats:styled-content>isease <jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>ctivity <jats:styled-content style=\"fixed-case\">S<\/jats:styled-content>core, <jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>merican <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>ollege of <jats:styled-content style=\"fixed-case\">R<\/jats:styled-content>heumatology criteria and clinical disease activity index. In this review we have reviewed the evolution of and changing need for these measures. The relevance of some measures and their use and limitations with reference to various characteristics are presented. Inflammation measures to quantify the <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> process is the best way to monitor <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> disease activity. C\u2010reactive protein alone or with other biomarkers to specify <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content>, appear to be good prospective measures.<\/jats:p>","DOI":"10.1111\/j.1756-185x.2012.01754.x","type":"journal-article","created":{"date-parts":[[2012,6,19]],"date-time":"2012-06-19T01:21:06Z","timestamp":1340068866000},"page":"239-248","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Measures in rheumatoid arthritis: are we measuring too many parameters"],"prefix":"10.1111","volume":"15","author":[{"given":"S.","family":"Chandrashekara","sequence":"first","affiliation":[{"name":"ChanRe Rheumatology and Immunology Center and Research Bangalore Karnataka India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Sachin","sequence":"additional","affiliation":[{"name":"ChanRe Rheumatology and Immunology Center and Research Bangalore Karnataka India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,6,18]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60784-3"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.10-3-248"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2010.02.007"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310302"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780241012"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330403"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780350502"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780360601"},{"key":"e_1_2_10_11_1","first-page":"579","article-title":"Development of a disease activity score based on judgment in clinical practice by rheumatologists","volume":"20","author":"van der Heijde DM","year":"1993","journal-title":"J Rheumatol"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380602"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380107"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390105"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22552"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30129"},{"issue":"18","key":"e_1_2_10_17_1","first-page":"S2","article-title":"Does partial control of inflammation prevent long\u2010term joint damage? Clinical rationale for combination therapy with multiple disease\u2010modifying antirheumatic drugs","volume":"17","author":"Pincus T","year":"1999","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_10_18_1","first-page":"61","article-title":"Rheumatoid arthritis. Understanding joint damage and inflammation","volume":"15","author":"Capriotti T","year":"2007","journal-title":"Adv Nurse Pract"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780350317"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/35.suppl_2.14"},{"key":"e_1_2_10_21_1","first-page":"644","article-title":"Pannus invasion and cartilage degradation in rheumatoid arthritis: involvement of MMP\u20103 and interleukin\u20101beta","volume":"23","author":"Ainola MM","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2009.04.048"},{"issue":"1","key":"e_1_2_10_23_1","first-page":"1","article-title":"Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti\u2010TNF alpha drugs","volume":"61","author":"Bombardieri S","year":"2009","journal-title":"Reumatismo"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2010.03.003"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.2009.090399"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.131573"},{"key":"e_1_2_10_27_1","first-page":"216","article-title":"Limitations of a quantitative swollen and tender joint count to assess and monitor patients with rheumatoid arthritis","volume":"66","author":"Pincus T","year":"2008","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem286"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02238547"},{"key":"e_1_2_10_30_1","first-page":"201","article-title":"Relative efficiencies of physician\/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials","volume":"35","author":"Pincus T","year":"2008","journal-title":"J Rheumatol"},{"key":"e_1_2_10_31_1","first-page":"R7","article-title":"Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST \u2013 RA study","volume":"11","author":"Sokka T","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"e_1_2_10_32_1","first-page":"884","article-title":"Relative sensitivity to change of the erythrocyte sedimentation rate and serum C \u2013 reactive protein concentration in rheumatoid arthritis","volume":"31","author":"Ward MM","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.11407"},{"key":"e_1_2_10_34_1","first-page":"535","article-title":"Sensitivity to change of rheumatoid arthritis clinical trial outcome measures","volume":"20","author":"Anderson JJ","year":"1993","journal-title":"J Rheumatol"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reuma.2010.11.018"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.59.12.966"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0300-8932(02)76764-X"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)90965-3"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23766"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/32.7.589"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.51.2.177"},{"issue":"39","key":"e_1_2_10_42_1","first-page":"S100","article-title":"The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis","volume":"23","author":"Aletaha D","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_10_43_1","first-page":"575","article-title":"Interpretation and power of a pooled index","volume":"20","author":"Goldsmith CH","year":"1993","journal-title":"J Rheumatol"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.081188"},{"key":"e_1_2_10_45_1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3899\/jrheum.081100","article-title":"How to assess patients with rheumatoid arthritis and concomitant fibromyalgia","volume":"36","author":"Makinen H","year":"2009","journal-title":"J Rheumatol"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16676-2"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21405"},{"key":"e_1_2_10_48_1","doi-asserted-by":"crossref","first-page":"S126","DOI":"10.1002\/art.23364","article-title":"Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the Best study): a randomized, controlled trial","volume":"58","author":"Goekoop\u2010Ruiterman YP","year":"2008","journal-title":"Arthritis Rheum"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24447"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3060"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00393-003-0516-9"},{"key":"e_1_2_10_52_1","first-page":"311","article-title":"Imaging methods in rheumatoid arthritis","volume":"19","author":"Fukae J","year":"2009","journal-title":"Clin Calcium"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep171"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh057"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq006a"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.11481"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23945"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22190"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006242"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02962246"},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s001340050837"},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.3109\/00016348809004199"},{"key":"e_1_2_10_63_1","first-page":"721","article-title":"Endothelial function, CRP and oxidative stress in chronic kidney disease","volume":"18","author":"Annuk M","year":"2005","journal-title":"J Nephrol"},{"key":"e_1_2_10_64_1","first-page":"2351","article-title":"The influence of age, sex, and race on the upper reference limit of serum C\u2010reactive protein concentration","volume":"27","author":"Wener MH","year":"2000","journal-title":"J Rheumatol"},{"key":"e_1_2_10_65_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/36.6.643"},{"key":"e_1_2_10_66_1","first-page":"533","article-title":"Serum matrix metalloproteinase\u20103 and fibrin degradation product levels correlate with clinical disease activity in rheumatoid arthritis","volume":"16","author":"Ichikawa Y","year":"1998","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_10_67_1","first-page":"251","article-title":"Circulating levels of matrix metalloproteinases MMP\u20103 and MMP\u20101, tissue inhibitor of metalloproteinases 1 (TIMP\u20101), and MMP\u20101\/TIMP\u20101 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers","volume":"26","author":"Keyszer G","year":"1999","journal-title":"J Rheumatol"},{"key":"e_1_2_10_68_1","first-page":"888","article-title":"Matrix metalloproteinase\u20103 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis","volume":"27","author":"Ribbens C","year":"2000","journal-title":"J Rheumatol"},{"key":"e_1_2_10_69_1","first-page":"21","article-title":"Role of procalcitonin and CRP in diagnosis and follow\u2010up of neonatal sepsis","volume":"49","author":"Koksal N","year":"2007","journal-title":"Turk J Pediatr"},{"key":"e_1_2_10_70_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-7-137"},{"key":"e_1_2_10_71_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00776-010-1498-5"},{"key":"e_1_2_10_72_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080770"},{"key":"e_1_2_10_73_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar2836"},{"issue":"43","key":"e_1_2_10_74_1","first-page":"S33","article-title":"Can remission be maintained with or without further drug therapy in rheumatoid arthritis?","volume":"24","author":"Saleem B","year":"2006","journal-title":"Clin Exp Rheumatol"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1756-185X.2012.01754.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1756-185X.2012.01754.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T17:23:44Z","timestamp":1698773024000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1756-185X.2012.01754.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":73,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["10.1111\/j.1756-185X.2012.01754.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1756-185x.2012.01754.x","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6]]},"assertion":[{"value":"2012-06-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}